Investor Relations

Here you will find details on our share as well as detailed information on key figures, annual and quarterly results, IR events and much more.

Q1 2021 results

HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due to a strong core business, consolidated sales (IFRS) increased by 22% to EUR 73.9 million in the first quarter of 2021. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased earnings disproportionately at all levels. The result from ordinary activities (EBITDA) rose by 196 % to EUR 2,823 thousand (previous year: EUR 954 thousand) and the operating result (EBIT) by 350 % to EUR 2,428 thousand. Thus, after the first three months of the current year, EBIT already exceeds the figure for 2020 as a whole. One reason for the increase in earnings is the improvement in the gross margin, which has increased from 7.2 % (previous year) to 9.8 % in the first quarter of 2021.

Rating & Research

Here you will find well-founded stock analyses of renowned research houses and banks on the HAEMATO AG share.

BUY: 52.50 €

GBC AG, 14. June 2021

BUY: 48.00 €

First Berlin, 22. April 2021


Lilienthalstraße 5c
12529 Schönefeld

Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79